We quantified the expression of IL-17A in tumor tissues using mean density values, and divided NSCLC patients into IL-17A low and high expression groups by the median of their expression level (Fig. 1C), and negative cases were classified as low expression group. This evidence concerns the gene IL17A and non-small cell lung carcinoma.